Market closed · Next open: Friday 9:30 AM ET
Last update: Nov 19, 2026, 6:14 PM ET
Pfizer Inc.
$27.54▼ 1.85% today
Market Closed

Why Pfizer Inc. (PFE) stock moved

No significant move on Nov 19, 2026 (−1.9%, close-to-close). Latest notable session: Nov 5, 2026.

Latest session▼ 3.0% · Nov 5, 2026 close

Why Pfizer Inc. (PFE) fell 3.0% on November 5, 2026

Pfizer Inc. (PFE) fell 3.0% on November 5, 2026, closing at $29.88 versus $30.79 the prior session (close-to-close, from daily closes). After reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products. Source: FMP price data; BestStocks detection.

Updated
Prior close
$30.79
Nov 5, 2026 close
$29.88
Change (close-to-close)
−$0.91
−2.96%
As first detected · Nov 5, 2026, 4:42 PM ET

Pfizer Inc. (PFE) moved -3.89% from $31.09 to $29.88 on 2026-11-05, two days after reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products.

What to watch next: Pfizer's next scheduled earnings are 2027-02-02 (consensus EPS estimate: $0.72).

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved PFE

  1. +2.6%Following a strong Q3 2026 earnings beat and raised full-year guidance.
  2. +3.0%Preview of over 50 abstracts for IDWeek 2026 (Oct 21–24), featuring new infectious disease clinical data including pneumococcal and RSV programs, per BusinessWire.

Pfizer Inc. (PFE) shares fell 1.9% to $27.54 as of November 20, 2026, a modest decline from the prior close of $28.06. BestStocks flagged the session as a major change for PFE. The move is tied to company news. Below, we break down what changed for PFE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

Pfizer secures $1.5 billion Blackstone co-funding for obesity drug berobenatide development through 2028. Risk-sharing deal reduces Pfizer's R&D burden while validating obesity program value; potential blockbuster market.

This summary describes the catalyst and move as first detected on Nov 11, 2026, 4:41 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsSector-Wide MoveLow confidence
Rel. volume
1.0×
Below Avg
Vs peers
Top 3 of 7 peers
In Line With Peers
Market cap
$157.0B
New York Stock Exchange
Analyst target
$32
+14.4% vs price
Price chart
Nov 20
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Pfizer Inc. investors

For Pfizer Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 1.9%; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in PFE's fundamentals. Wall Street's consensus price target sits at $31.50, implying +14.4% upside from $27.54. BestStocks rates the overall signal quality low (48/100). With earnings roughly 74 days out, the next report is the most likely near-term test of the move.

PFE price reaction

PFE last traded at $27.54, down $0.52 (-1.85%) from the previous close of $28.06. The session traded on 1.0× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -2.3% over the same stretch, leaving PFE essentially in line with peers.

Bullish and bearish analyst opinions on Pfizer Inc. (PFE)

Latest catalysta bearish counterpoint
The latest catalyst — negative company news — a bearish counterpoint that challenges the prevailing bullish analyst view.

The consensus analyst price target on Pfizer Inc. (PFE) is $31.50, 14.4% above the recent $27.54. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PFE line up.

The bullish case

  • Wall Street's consensus price target of $31.50 implies +14.4% upside from $27.54.
  • The Street's most bullish target is $40.00 (+45.2%).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $27.00 (-2.0%).
  • Negative session, down 1.9%.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $32+14.4%
= 10 maintains
Freedom Broker maintained Buy · 2026-11-06
SEC filings watch
10-Q2026-11-03
Quarterly financial results
medium
8-K2026-11-03
Material event — review for impact
high
8-K2026-11-03
Material event — review for impact
high
8-K2026-08-04
Material event — review for impact
high
Peer context
PFE-1.9%
LLY-2.3%
UNH-5.6%
JNJ-2.0%
ABBV-0.9%
MRK-3.6%

Previous notable changes for PFE

News2026-11-19
Pfizer maintains 352-year consecutive quarterly dividend streak with December 7 payment.
News2026-11-18
Analyst argues Pfizer's patent cliff risks are exaggerated despite upcoming three-year expiration cycle.
News2026-11-17
Pfizer CEO projects high single-digit growth post-patent cliff via new medicines and pipeline expansion.
Material / Earnings2026-11-03
Pfizer Inc. (PFE) reported EPS of $0.87 vs. consensus estimate of $0.73, beating by 18.4% on 2026-11-03.
Upcoming catalysts & outlook
Next earnings
2027-02-02 (est.)
in 74 days
Thesis shift
Neutral / Mixed
bearish signal
Risk level
Low
from change events

Frequently asked questions about PFE

Why did Pfizer Inc. (PFE) stock move?

Pfizer Inc. (PFE) fell 3.0% on November 5, 2026, closing at $29.88 versus $30.79 the prior session (close-to-close, from daily closes). After reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products. Source: FMP price data; BestStocks detection.

How much did PFE stock fall?

PFE lost 1.85% ($0.52) versus the prior close of $28.06, last trading at $27.54 on 1.0× average volume.

When is Pfizer Inc.'s next earnings date?

PFE's next earnings report is estimated for 2027-02-02 — about 74 days away.

What is the analyst price target for PFE?

The consensus analyst price target for PFE is $31.50, about 14.4% above the current $27.54. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.

Is the PFE move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -2.3% against PFE's -1.9%. PFE ranks top 3 of 7 peers.

How BestStocks tracks PFE

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for PFE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsCompany news feedsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.